Search clinical trials for: Xarelto (Rivaroxaban)

Total 482 results

Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
Jilin University

Recruiting

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)

ST-segment Elevation Myocardial Infarction (STEMI) | Left Ventricular Thrombus

China
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

Canada
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
University of Padova

Terminated

Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)

Antiphospholipid Syndrome

Italy
Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
Bayer
Janssen R&D, L.L.C.

Completed

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Atrial Fibrillation

Indonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Venous Thrombosis | Pediatrics

Italy, United States, Austria, Australia, Canada, France, Switzerland, Germany, Israel, Ireland
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
State University of New York - Upstate Medical...

Terminated

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

Gastric Bypass Status

United States
University Hospital, Grenoble

Completed

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics (REVNEWANTICO)

Venous Thromboembolism

France
Chiayi Christian Hospital

Recruiting

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Arthroplasty | Venous Thromboembolism

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
Bayer

Completed

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Treatment of Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (XANTUS-EL)

Atrial Fibrillation

Colombia, Kazakhstan, Mexico, Russian Federation, Argentina, Azerbaijan, Bahrain, Chile, Egypt, Georgia, Jordan, Kenya, Lebanon, Saudi Arabia, United Arab Emirates, Uruguay, Venezuela
Bayer
Janssen Research & Development, LLC

Completed

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (NEURO-XAR)

Stroke | Embolism

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (SOPRANO)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Russian Federation
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA)

Atrial Fibrillation

France, Germany, Turkey, Russian Federation, Bulgaria, Ukraine, Poland
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Therapeutic Equivalency

Germany
Bayer
Janssen Research & Development, LLC

Completed

Real-world Dosing Patterns of Rivaroxaban in the United States

Atrial Fibrillation

United States
University of Alberta

Completed

Rivaroxaban in Type 2 Myocardial Infarctions (R2MI)

Type II Myocardial Infarction

Canada
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (Einstein Jr)

Thromboembolism

Spain, Austria, Israel, Italy, France, Turkey, Germany
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
Second Xiangya Hospital of Central South University

Completed

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

China
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism... and other collaborators

Not yet recruiting

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (PREVENT-GU)

Venous Thromboembolism | Urologic Cancer
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
University of Michigan

Withdrawn

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Complications; Arthroplasty

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan

Search clinical trials for: Xarelto (Rivaroxaban)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations